版本:
中国

BRIEF-Incyte Corp provides additional Phase 1 Data from ECHO-202 trial

Oct 7 Press Release :

* Additional phase 1 data from ECHO-202 reinforce durability of response in patients with treatment-naive advanced or metastatic melanoma treated with epacadostat in combination with keytruda (pembrolizumab)

* Says epacadostat in combination with pembrolizumab was well tolerated in Phase 1 population Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐